Related Experiment Video
Updated: Jul 6, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Prevalence and Impact of Cardiovascular Comorbidities on Disease Outcomes in a Middle Eastern Chronic Lymphocytic
Salem H Alshemmari1,2, Ahmed Alsarraf3, Abdulaziz Dashti4
1Department of Medicine, Kuwait University, Kuwait City, Kuwait, salem61@gmail.com.
Insights
Comorbidities like vascular disease and diabetes mellitus significantly impact survival for chronic lymphocytic leukemia (CLL) patients. Integrated management is crucial, especially in high-risk populations.
Area of Science:
- Hematology
- Oncology
- Epidemiology
Background:
- Chronic lymphocytic leukemia (CLL) survival is influenced by comorbidities.
- Kuwait has a high prevalence of cardiometabolic diseases, necessitating research into their impact on CLL patients.
Purpose of the Study:
- To assess the prevalence of comorbidities in Kuwaiti CLL patients.
- To determine the prognostic significance of comorbidities, especially diabetes mellitus and vascular disease, on survival outcomes in CLL.
Main Methods:
- Retrospective cohort study of 316 CLL patients (2008-2021) at Kuwait Cancer Control Centre.
- Data collected on demographics, clinical details, and comorbidities from medical records.
- Overall survival (OS) analyzed using Kaplan-Meier curves and Cox proportional hazards models.
Main Results:
- Most common comorbidities: hypertension (44%), diabetes mellitus (42%), dyslipidemia (10%).
- Vascular disease strongly associated with inferior OS (adjusted HR 2.96; p=0.004).
- Diabetes mellitus also linked to increased mortality (HR 1.74; p=0.034); unmutated IGHV status correlated with worse survival (p<0.001).
Conclusions:
- Comorbidities, particularly vascular disease and diabetes mellitus, significantly impact CLL patient survival.
- Integrated management strategies addressing both CLL and comorbidities are vital.
- Findings are especially relevant for populations with high cardiometabolic risk.
Objectives:
We aimed to investigate the prevalence of comorbidities including diabetes mellitus (DM), hypertension, dyslipidemia, and cardiovascular disease in the Middle Eastern chronic lymphocytic leukemia (CLL) population and their correlation with disease outcome at the Kuwait Cancer Control Center (KCCC).
Methods:
We performed a retrospective study of the CLL patients diagnosed in the KCCC between 2008 and 2021. The hazards ratio (HR) of death was calculated using Cox regression analysis. Statistical analysis was performed using SPSS (v27).
Results:
A total of 316 patients had recorded comorbidities. The mean age at diagnosis was 60 years (SD + 13) with a male-to-female ratio of 3:1. Of these, 140 (44%) had hypertension, 132 (42%) had DM, and 32 (10%) had dyslipidemia. Nineteen CLL patients (6%) had vascular disease at diagnosis and 48 (15%) had a cardiac disease. The HR of death in patients with DM, hypertension, and dyslipidemia was 1.74 (1.04-2.89; p value 0.034), 1.14 (0.68-1.91; p value 0.628), and 1.91 (0.91-3.77; p value 0.063), respectively. The vascular disease and the cardiac disease were associated with HR of death of 3.48 (1.69-7.15; p value <0.001) and 1.39 (0.74-2.61; p value 0.312), respectively. In the multivariate analysis, vascular comorbidities remained as an independent predictor of death with an HR of 2.96 (1.41-6.21; p value = 0.004).
Conclusion:
The cardiovascular disease and associated risk factors are prevalent in the Kuwaiti CLL patients, and they are also associated with an unfavorable prognosis.
Related Concept Videos
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease III: Medical Management
Heart Failure III: Clinical Manifestations
Hypertension III: Clinical Manifestations and Diagnostic Studies
Chronic Kidney Disease II: Clinical Manifestations
